Ovid Therapeutics Inc.
OVID
$1.22
$0.087.02%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 3,611.24% | -12.16% | -46.48% | 58.72% | 125.33% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3,611.24% | -12.16% | -46.48% | 58.72% | 125.33% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 3,611.24% | -12.16% | -46.48% | 58.72% | 125.33% |
| SG&A Expenses | -39.78% | -16.00% | 9.49% | -18.53% | 11.81% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -45.16% | -27.81% | -33.87% | 10.39% | 56.16% |
| Operating Income | 75.27% | 27.94% | 33.76% | -9.95% | -55.76% |
| Income Before Tax | -154.97% | 12.48% | 39.61% | -24.46% | 168.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -154.97% | 12.48% | 39.61% | -24.46% | 168.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -154.97% | 12.48% | 39.61% | -24.46% | 168.67% |
| EBIT | 75.27% | 27.94% | 33.76% | -9.95% | -55.76% |
| EBITDA | 75.58% | 28.19% | 34.17% | -9.88% | -56.26% |
| EPS Basic | -154.78% | 14.39% | 39.23% | -23.85% | 167.14% |
| Normalized Basic EPS | -161.95% | 24.63% | 38.74% | -23.80% | 165.78% |
| EPS Diluted | -154.78% | 14.39% | 39.45% | -25.00% | 165.61% |
| Normalized Diluted EPS | -162.14% | 24.63% | 38.74% | -23.80% | 165.58% |
| Average Basic Shares Outstanding | 0.27% | 0.46% | 0.46% | 0.51% | 0.54% |
| Average Diluted Shares Outstanding | -0.13% | 0.46% | 0.46% | 0.51% | 0.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |